16:16 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

ZZ Biotech's 3K3A-APC reduces hemorrhage rate in Phase II for acute ischemic stroke

ZZ Biotech LLC (Houston, Texas) reported preliminary data from the Phase II RHAPSODY trial in 110 patients with moderate to severe acute ischemic stroke who were treated with IV tissue plasminogen activator (tPA), intra-arterial thrombectomy...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Activated protein C (APC)

Neurology INDICATION: Stroke Mouse studies suggest human neuronal stem cell (NSC) grafts combined with the human APC variant 3K3A-APC could help treat stroke. In a mouse model of middle cerebral artery occlusion, transplants of human...
07:00 , Apr 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology; stroke Protease-activated receptor 1 (PAR1); PAR3 Cell culture studies suggest PAR1 and PAR3 agonists could be useful for stimulating neural regeneration in ischemic stroke...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

3K3A-APC: Phase I started

Socratech's ZZ Biotech LLC company began a double-blind, placebo-controlled, Austrian Phase I trial to evaluate single and multiple ascending-doses of up to 720 µg/kg IV 3K3A-APC in about 62 healthy volunteers. Socratech LLC , Rochester,...